Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Accolade Release 11.2

6 Jul 2017 07:00

RNS Number : 2492K
Sopheon PLC
06 July 2017
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Sopheon's Accolade 11.2 Introduces New Analytics Capabilities to Enable Actionable Insights

 

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Management, announces today the latest version of its Accolade® Enterprise Innovation Management (EIM) solution.

'Good' decisions are based on the availability of 'good' information - having meaningful, trusted and current data at your fingertips at the moment you need it. Business leaders driving decision-centric processes should be drawing on comprehensive information that is generated internally as well as gleaned from outside the company. Sopheon has long focused on surfacing relevant and timely information to support better, faster decisions; with the release of Accolade version 11.2, Sopheon offers new analytic and knowledge discovery capability to more proactively manage risk and create breakthrough innovations with increased efficiency. The new capability - named Accolade Insights - offers a range of benefits.

Further Connecting the Enterprise

Speed to informed decisions, critical in a fast-moving, digital business environment, depends on data that is timely, accurate, situationally aware and actionable. Accolade Insights automatically leverages and connects internal and external data sources to proactively consolidate and serve up intellectual 'assets' at the point a decision needs to be made. These assets include relevant experts and expertise, learnings from past work, and external macroeconomic changes impacting critical assumptions underpinning business forecasts and key performance indicators.

Pre-empting Risk and Improving Accuracy of Business Forecasts

Accolade Insights was designed to help companies leverage internal data in combination with macroeconomic and other external factors for real-time monitoring of the health status of products, portfolios and projects, including the business case assumptions impacting accuracy of revenue and profit forecasts. This is equally applicable to the management of new product introductions, in-market products, product lines and market segments.

When shown a preview of this functionality, a $14 billion industrial manufacturing customer stated: "Some time ago we had what we thought was a great innovation, but the macroeconomics shifted in the middle of our product development cycle. In the end we went to market with a product that failed because we didn't proactively adjust to the shift. Had I had this early visibility of the business case impact of the market dynamics, it would have saved us millions of dollars."

Stimulating Innovation & Improving Efficiency through Proactive Knowledge Reuse

Many companies encounter redundancy of innovation effort. They waste time and money on duplicating work that has been done before; recreating experience that has been 'lost' when key employees have left, repeating the same mistakes project after project because lessons learned are not codified and shared; or not being aware of technology or other developments that could be reused to shorten the time required to develop breakthrough innovations. Accolade automatically captures cross-functional work activity and work product, which become a rich asset for reuse.

One long-standing Sopheon customer proudly relates how a breakthrough technology developed by a packing business unit to retain freshness in bags of crisps, was successfully reused for entirely different applications in aero and auto by another division, generating millions in new revenue. The 'discovery' of the technology that was reused was enabled through Accolade.

 

Sopheon's CEO Andy Michuda, said: "Sopheon has long focused on making relevant and timely information available to support better, faster decisions. Accolade 11.2 automatically leverages and connects internal and external data sources through Accolade Insights, allowing customers to proactively manage risk and create breakthrough innovations with more efficiency."

 

 

 

Sopheon® and Accolade® are trademarks of Sopheon 

 

 

 

 

For further information contact:

Barry Mence, ChairmanArif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / Giles Rolls (corporate finance)

Mia Gardener (corporate broking)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAOKPDBABKDPOK
Date   Source Headline
6th Dec 20137:00 amRNSDirector/PDMR Shareholding
5th Dec 20137:00 amRNSCorporate Update
19th Nov 20137:00 amRNSSopheon Delivers Accolade® Release 9.0
7th Nov 20137:00 amRNSInterim Management Statement
11th Sep 20133:00 pmRNSHolding(s) in Company
4th Sep 20133:00 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSInterim Results
15th Aug 20133:00 pmRNSHolding(s) in Company
29th Jul 20133:00 pmRNSHolding(s) in Company
26th Jul 20137:00 amRNSTrading Update
15th Jul 20134:15 pmRNSHolding(s) in Company
28th Jun 20133:00 pmRNSTotal Voting Rights
27th Jun 20133:00 pmRNSHolding(s) in Company
19th Jun 20133:42 pmRNSHolding(s) in Company
19th Jun 20137:00 amRNSNew capabilities with Accolade(R) 8.3
14th Jun 20132:00 pmRNSContract Win
12th Jun 201312:00 pmRNSResult of AGM & GM
12th Jun 20137:00 amRNSAGM Statement
4th Jun 20137:00 amRNSIssue of Shares
2nd May 20137:00 amRNSInterim Management Statement
21st Mar 20137:00 amRNSPreliminary Results
30th Jan 20137:00 amRNSTrading Update
23rd Jan 20137:00 amRNSLaunch of Accolade 8.2
7th Dec 201211:36 amPRNHolding(s) in Company
8th Nov 20127:00 amPRNInterim Management Statement
1st Oct 20127:00 amRNSHolding(s) in Company
1st Oct 20127:00 amRNSDirectors' Options
24th Sep 20127:00 amRNSMarket Transfer to NYSE Alternext Concluded
23rd Aug 20127:00 amRNSAmendment to Terms of Convertible Loan Stock
23rd Aug 20127:00 amRNSInterim Results
23rd Jul 20127:00 amRNSTrading Update
13th Jun 20123:14 pmRNSResult of AGM
13th Jun 20127:00 amRNSAGM Statement
15th May 20127:00 amRNSAmendment to terms of Convertible Loan Stock
3rd May 20127:00 amRNSInterim Management Statement
25th Apr 20127:00 amRNSLaunch of Accolade 8.0
22nd Mar 20127:00 amRNSPreliminary Results
16th Feb 20127:00 amRNSTop 10 Solution Provider to CGM
31st Jan 20127:00 amRNSTrading Update
23rd Dec 201112:32 pmRNSExtension of GEM Equity Line
23rd Dec 201112:29 pmRNSTrading Update
5th Dec 201112:40 pmRNSHolding(s) in Company
3rd Nov 20117:00 amRNSInterim Management Statement
25th Aug 20117:00 amRNSInterim Results
25th Jul 20117:00 amRNSTrading Statement
23rd Jun 20112:15 pmRNSDirector/PDMR Shareholding
15th Jun 20117:00 amRNSAGM Statement
5th May 20117:00 amRNSInterim Management Statement
24th Mar 20117:00 amRNSPreliminary Results
10th Feb 20117:00 amPRNAppointment of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.